Current status and challenges of CAR-T cell therapy in the treatment of haematological cancer

Open Access

Issue		BIO Web Conf. Volume 182, 2025 The 3^rd International Conference on Food Science and Bio-medicine (ICFSB 2025)


Article Number		02001
Number of page(s)		6
Section		Biomedical Research and Applications
DOI		https://doi.org/10.1051/bioconf/202518202001
Published online		02 July 2025

A. Hall, M. Lynagh, J. Bryant, R. Sanson-Fisher, Supportive care needs of hematological cancer survivors: a critical review of the literature. Crit. Rev. Oncol. Hematol. 88, 102–116 (2013). [Google Scholar]
R.L. Siegel, K.D. Miller, A. Goding Sauer, S.A. Fedewa, L.F. Butterly, J.C. Anderson, ... A. Jemal, Colorectal cancer statistics, 2020. CA: Cancer J. Clin. 70, 145–164 (2020). [CrossRef] [PubMed] [Google Scholar]
M. Cao, W. Chen, Chin. J. Front. Interpretation on the global cancer statistics of GLOBOCAN 2020 [J]. Med. Sci. (Electron. Vers.) 13, 63–69 (2021). [Google Scholar]
E. Voynova, D. Kovalovsky, From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives. Cells 10, 2845 (2021). [CrossRef] [PubMed] [Google Scholar]
M. Wang, J. Munoz, A. Goy, F.L. Locke, C.A. Jacobson, B.T. Hill, ... P.M. Reagan, official journal of the ALong-Term Follow-Up of Combination of BCell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J. Clin. Oncol. 40, 2246–2256 (2022). [Google Scholar]
S.L. Maude, T.W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, ... S.A. Grupp, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439–448 (2018). [Google Scholar]
S.J. van der Stegen, M. Hamieh, M. Sadelain, Nat. Rev. The pharmacology of second-generation chimeric antigen receptors. Nature reviews. Drug Discov. 14, 499–509 (2015). [Google Scholar]
N.C. Munshi, L.D. Anderson Jr, N. Shah, D. Madduri, J. Berdeja, S. Lonial, ... J. San-Miguel, Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N. Engl. J. Med. 384, 705–716 (2021). [Google Scholar]
M. Chmielewski, H. Abken, Current developments and clinical translation. Adv. Cell Gene Ther. 3, e84 (2020). [CrossRef] [Google Scholar]
Y. Kagoya, S. Tanaka, T. Guo, M. Anczurowski, C.H. Wang, K. Saso, ... N. Hirano, A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352–359 (2018). [Google Scholar]
L. Poirot, B. Jahangiri, P. Duchateau, J. Valton, Allogeneic CAR T-cells resistant to both T-and NKcell cytotoxicity[J]. Cytotherapy 22, S134–S135 (2020). [Google Scholar]
P. Dabas, A. Danda, Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy[J]. Med. Oncol. 40, 275 (2023). [Google Scholar]
M.L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, ... R. Brentjens, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25–224ra25 (2014). [Google Scholar]
J.N. Kochenderfer, M.E. Dudley, S.H. Kassim, R.P. Somerville, R.O. Carpenter, M. Stetler-Stevenson, ... S.A. Rosenberg, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015). [Google Scholar]
S. Mailankody, S.M. Devlin, J. Landa, K. Nath, C. Diamonte, E.J. Carstens, ... E.L. Smith, GPRC5DTargeted CAR T Cells for Myeloma. N. Engl. J. Med. 387, 1196–1206 (2022). [Google Scholar]
N. Raje, J. Berdeja, Y. Lin, D. Siegel, S. Jagannath, D. Madduri, ... J.N. Kochenderfer, Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 380, 1726–1737 (2019). [Google Scholar]
Y. Wang, J. Cao, W. Gu, M. Shi, J. Lan, Z. Yan, ... K. Xu, J. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. Clin. Oncol. 40, 2246–2256 (2022). [Google Scholar]
H. Mei, C. Li, H. Jiang, X. Zhao, Z. Huang, D. Jin, ... Y. Hu, A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J. Hematol. Oncol. 14, 1–17 (2021). [Google Scholar]
E. Zah, E. Nam, V. Bhuvan, U. Tran, B.Y. Ji, S.B. Gosliner, ... Y.Y. Chen, Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat. Commun. 11, 2283 (2020). [Google Scholar]
C.Z. Qi, V. Bollu, H. Yang, A. Dalal, S. Zhang, J. Zhang, Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. Clin. Ther. 43, 1300–1319 (2021). [CrossRef] [Google Scholar]
A. Juillerat, D. Tkach, M. Yang, A. Boyne, J. Valton, L. Poirot, P. Duchateau, Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells. Front. Bioeng. Biotechnol. 8, 678 (2020). [Google Scholar]
M.A. Morgan, H. Büning, M. Sauer, A. Schambach, Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells. Front. Immunol. 11, 1965 (2020). [Google Scholar]
V. Staedtke, R.Y. Bai, K. Kim, M. Darvas, M.L. Davila, G.J. Riggins, ... S. Zhou, Disruption of a selfamplifying catecholamine loop reduces cytokine release syndrome. Nature 564, 273–277 (2018). [Google Scholar]
I. Abou Dalle, R. Dulery, N. Moukalled, L. Ricard, N. Stocker, J. El-Cheikh, ... A. Bazarbachi, Biand Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives. Blood Cancer J. 14, 23 (2024). [CrossRef] [PubMed] [Google Scholar]
P. Winidmanokul, A. Panya, S. Okada, Tri-specific killer engager: unleashing multi-synergic power against cancer. Explor. Target. Anti-tumour Ther. 5, 432 (2024). [Google Scholar]
M. Mamonkin, M. Mukherjee, M. Srinivasan, S. Sharma, D. Gomes-Silva, F. Mo, ... M.K. Brenner, Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol. Res. 6, 47–58 (2018). [CrossRef] [PubMed] [Google Scholar]
J. Tipanee, E. Samara-Kuko, T. Gevaert, M.K. Chuah, T. VandenDriessche, Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol. Ther. 30, 3155–3175 (2022). [Google Scholar]
V. Wiebking, J.O. Patterson, R. Martin, M.K. Chanda, C.M. Lee, W. Srifa, ... M.H. Porteus, Metabolic engineering generates a transgene-free safety switch for cell therapy. Nat. Biotechnol. 38, 1441–1450 (2020). [Google Scholar]
K.C. Straathof, M.A. Pule, P. Yotnda, G. Dotti, E.F. Vanin, M.K. Brenner, ... C.M. Rooney, An inducible caspase 9 safety switch for T-cell therapy. Blood 106, 1525–1533 (2005). [PubMed] [Google Scholar]
H. Juillerat, D. Tkach, M. Yang, A. Boyne, J. Valton, L. Poirot, P. Duchateau, Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells. Front. Bioeng. Biotechnol. 8, 678 (2020). [Google Scholar]
M.A. Morgan, H. Büning, M. Sauer, A. Schambach, Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells. Front. Immunol. 11, 1965 (2020). [Google Scholar]
V. Staedtke, R.Y. Bai, K. Kim, M. Darvas, M.L. Davila, G.J. Riggins, ... S. Zhou, Disruption of a selfamplifying catecholamine loop reduces cytokine release syndrome. Nature 564, 273–277 (2018). [Google Scholar]
I. Abou Dalle, R. Dulery, N. Moukalled, L. Ricard, N. Stocker, J. El-Cheikh, ... A. Bazarbachi, Biand Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives. Blood Cancer J. 14, 23 (2024). [CrossRef] [PubMed] [Google Scholar]
P. Winidmanokul, A. Panya, S. Okada, Tri-specific killer engager: unleashing multi-synergic power against cancer. Explor. Target. Anti-tumour Ther. 5, 432 (2024). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.